Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Research Square|April 17, 2023
Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over TimeAdnan Shaaban, Ashley Petersen, Heather Beckwith, et al.
Cardio-Oncology (London, England)|May 1, 2024
Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over timeAdnan Shaaban, Ashley Petersen, Heather Beckwith, et al.
Faculty Reviews|March 4, 2021
Recent advances in neoadjuvant therapy for breast cancerDavid A Potter, César A Herrera-Ponzanelli, Diego Hinojosa, et al.
Oncology Nursing Forum|July 2, 2008
Oncology outpatient and provider responses to a computerized symptom assessment systemJanet S Carpenter, Susan Rawl, Jennifer Porter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2011
The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivinAnjaiah Srirangam, Monica Milani, Ranjana Mitra, et al.
Molecular Cancer Therapeutics|November 13, 2008
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicityFarnaz Yamoutpour, Vidya Bodempudi, Shay E Park, et al.
The Journal of Biological Chemistry|March 16, 2011
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET)Ranjana Mitra, Zhijun Guo, Monica Milani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancerAnjaiah Srirangam, Ranjana Mitra, Mu Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
Pageof 3